SCHEDULE: Frazier Life Sciences Discloses Allogene Stake

Frazier Life Sciences entities filed a Schedule 13G reporting a combined beneficial ownership of approximately 4.7% in Allogene Therapeutics, Inc.

Summary

• Frazier Life Sciences Public Fund, L.P. and affiliated entities reported beneficial ownership of 16,205,306 shares of Allogene Therapeutics, Inc. common stock.
• The reporting entities collectively hold a 4.7% stake in the company.
• The ownership percentage is based on a total of 343,977,920 shares outstanding, accounting for both the March 10, 2026, 10-K filing and the April 16, 2026, share issuance.
• The filing is a standard Schedule 13G, indicating the shares are held for investment purposes without the intent to influence control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing institutional holdings without signaling a change in strategic direction or control.

Positives

• The filing confirms continued institutional investment interest in Allogene Therapeutics.
• The reporting entities have certified that the shares are not held for the purpose of changing or influencing control of the issuer.

Negatives

• The reporting entities hold less than 5% of the company's outstanding shares, which may limit their influence on corporate governance compared to larger institutional holders.

Risks

• The investment is subject to the general market risks associated with the biotechnology sector and the specific clinical development risks of Allogene Therapeutics.
• The ownership percentage is subject to dilution based on future equity offerings or corporate actions by the issuer.

Future Outlook

The reporting persons state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional portfolio management within the biotech sector, where venture capital and specialized life science funds maintain positions in clinical-stage companies following public offerings.

Comparison to Industry Standards

• The filing follows standard SEC disclosure requirements for institutional investors holding significant but non-controlling interests in publicly traded biotech firms.
• The methodology for calculating ownership percentage aligns with standard regulatory practices for companies that have recently completed follow-on equity offerings.

Stakeholder Impact

• Shareholders may view the continued presence of Frazier Life Sciences as a sign of institutional confidence in the company's long-term prospects.

Next Steps

• The reporting persons will continue to monitor their investment in Allogene Therapeutics in accordance with their internal investment mandates.

Key Dates

Keywords

Allogene Therapeutics, Frazier Life Sciences, Schedule 13G, Biotechnology, Institutional Ownership, Common Stock